|
業務類別
|
Biotechnology |
|
業務概覽
|
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage. |
| 公司地址
| 500 Boylston Street, Suite 1350, Boston, MA, USA, 02116 |
| 電話號碼
| +1 617 655-6580 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.vorbio.com |
| 員工數量
| 76 |
| Dr. Jeremy Brett Sokolove, M.D. |
Chief Medical Officer |
-- |
27/04/2026 |
| Mr. Sandesh Mahatme, L.L.M. |
Chief Financial Officer, Chief Business Officer and Principal Accounting Officer |
美元 217.85K |
27/04/2026 |
| Dr. Qing Zuraw |
Chief Development Officer |
美元 243.39K |
22/07/2025 |
| Mr. Jean-Paul Kress, M.D. |
Chief Executive Officer, President and Chairman of the Board |
美元 344.62K |
27/04/2026 |
|
|
| Dr. Michel Detheux, PhD |
Independent Director |
27/04/2026 |
| Dr. Andrew Levin, M.D.,PhD |
Independent Director |
27/04/2026 |
| Dr. Fouad Namouni, M.D. |
Independent Director |
27/04/2026 |
| Mr. Wouter Joustra |
Independent Director |
27/04/2026 |
| Ms. Daniella Beckman |
Lead Independent Director |
27/04/2026 |
| Mr. Erez Kalir |
Independent Director |
27/04/2026 |
| Mr. Alexander G. Cumbo |
Independent Director |
27/04/2026 |
| Mr. Jean-Paul Kress, M.D. |
Chief Executive Officer, President and Chairman of the Board |
27/04/2026 |
|
|
|
|
